Bridge­Bio bor­rows $750M ahead of key PhI­II read­out, as it looks to wrap up buzzy 2021

4 years ago
Financing

Covid-19 roundup: Pfiz­er lands mas­sive $5B+ deal with US for po­ten­tial pill; Boost­ers for all adults are in­com­ing

4 years ago
Coronavirus

Are the stars lin­ing up for a ma­jor M&A deal at No­var­tis?

4 years ago
Bioregnum

No­vo Nordisk swal­lows Dicer­na and its RNAi pipeline in $3.3B buy­out

4 years ago
Deals

Mer­ck­'s Keytru­da scores first win in ad­ju­vant kid­ney can­cer, giv­ing it a leg up on check­point in­hibitor ri­vals

4 years ago
FDA+

An RA-backed start­up 'AT­AC­s' a nov­el chal­lenge, look­ing to spur pro­tein degra­da­tion out­side the cell

4 years ago
Financing
Startups

Gilead goes all in on its Ar­cus al­liance, pay­ing $725M cash for rights to a slate of can­cer drugs. And there's no ...

4 years ago
Deals
Cell/Gene Tx

Pas­sive vac­ci­na­tion? As­traZeneca spot­lights six-month pro­tec­tion with Covid-19 an­ti­body among vul­ner­a­ble group

4 years ago
R&D
Coronavirus

Flag­ship's ma­chine learn­ing start­up Gen­er­ate bags $370M in lat­est round with plans for a big hir­ing spree

4 years ago
Financing

Sanofi inks ma­jor AI deal to im­prove clin­i­cal de­vel­op­ment odds with $270M cash in­vest­ment

4 years ago
Deals
AI

Aca­dia teams with sto­ry­telling gi­ant Sto­ryCorps to record Parkin­son’s sto­ries — and erase stig­ma

4 years ago
Pharma
Marketing

FDA+ roundup: ALS bill would pro­vide $100M an­nu­al­ly to ac­cess po­ten­tial drugs; FDA needs to bet­ter en­force ...

4 years ago
Cell/Gene Tx
FDA+

Cures 2.0: Bi­par­ti­san House bill would al­low RWE to sat­is­fy con­fir­ma­to­ry tri­al re­quire­ments for ac­cel­er­at­ed ap­provals

4 years ago
FDA+

Pfiz­er on the hunt for a new CFO as Frank D'Ame­lio re­tires af­ter near­ly 15 years

4 years ago
People

Ahead of ex­pect­ed EU ob­jec­tions, Il­lu­mi­na de­fends Grail ac­qui­si­tion

4 years ago
Deals
Pharma

Ven­ture fund starts an­ti­body biotech in Delaware; CRO changes pri­vate eq­ui­ty hands

4 years ago
News Briefing

Cas­sava's prob­lems just got much worse as SEC launch­es probe in­to da­ta ma­nip­u­la­tion claims — re­port

4 years ago
R&D
FDA+

UP­DATE: Re­ports of small­pox-la­beled vials at Mer­ck plant con­tained 'no trace' of virus

4 years ago
Manufacturing

Does bio­phar­ma sup­port the Califf nom for FDA? Yeah, what­ev­er

4 years ago
Bioregnum

Eu­ro­pean drug reg­u­la­tor votes down Bio­gen's con­tro­ver­sial Alzheimer's drug

4 years ago
FDA+

In a sur­prise move, Flag­ship's Va­lo Health and Khosla Ven­tures SPAC call off merg­er

4 years ago
Financing

Covid-19 roundup: CDC ad­vi­so­ry com­mit­tee to dis­cuss Pfiz­er/BioN­Tech boost­ers for all adults; US buys up $1B in ...

4 years ago
Coronavirus

Covid-19 pill could add an­oth­er $15-25B to Pfiz­er's al­ready tor­rid pan­dem­ic cash flow — an­a­lyst

4 years ago
Coronavirus

In wake of PhII flop, Roche walks away from $350M Covid-19 an­tivi­ral pact

4 years ago
Deals
Coronavirus
First page Previous page 612613614615616617618 Next page Last page
A service from the Financial Times